Hanmi Pharmaceutical Company Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Hanmi Pharmaceutical Company Limited sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).

25 total trials 7 currently recruiting 15 completed early-phase tilt top decile by trial count

Hanmi Pharmaceutical Company Limited: 25 sponsored US clinical trials, 7 recruiting.

Hanmi Pharmaceutical Company Limited sponsors 25 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 15 completed. 1 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 3 trials.

Top-decile sponsor footprint

Hanmi Pharmaceutical Company Limited ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

15 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

25 total, page 1 of 1

RECRUITING Phase 2

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07527650
RECRUITING Phase 2

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900
RECRUITING Phase 1

A Single Ascending Dose Study of HM17321 in Healthy Adult Participants

NCT07219589
RECRUITING Phase 1

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT06724016
RECRUITING Phase 1

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

NCT06234397
RECRUITING Phase 2

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

NCT04732416
RECRUITING Phase 2

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706
ACTIVE NOT RECRUITING Phase 2

Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

NCT04505436
COMPLETED Phase 1

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098
COMPLETED Phase 1

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
COMPLETED Phase 1

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
COMPLETED Phase 1

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

NCT03744182
COMPLETED Phase 1

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

NCT03374241
COMPLETED Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
TERMINATED Phase 1

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

NCT03332836
COMPLETED Phase 1

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314
TERMINATED Phase 2

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

NCT02485652
COMPLETED Phase 1

Molar Potency Study of HM12470 in Healthy Subjects

NCT03330327
COMPLETED Phase 2

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02081118
COMPLETED Phase 2

Effect of LAPS-Exendin on Body Weight in Obese Population

NCT02075281
COMPLETED Phase 2

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
COMPLETED Phase 1

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
COMPLETED Phase 2

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
COMPLETED Phase 1

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

NCT01037543
COMPLETED Phase 1

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

NCT01030315

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 10
Phase 3 1

Therapeutic Areas

Obesity 3
Obese 2
Type 2 Diabetes Mellitus 2
Advanced or Metastatic Solid Tumors 2
Healthy 2
Short Bowel Syndrome 1
Renal Impairment 1
Type 2 Diabetes 1
NASH - Nonalcoholic Steatohepatitis 1
Type 1 Diabetes Mellitus 1

What is open in the Hanmi Pharmaceutical Company Limited pipeline

7 recruiting of 25 indexed (28% open); 15 completed (60%).

Phase mix: 1 late (III/IV) vs 24 early (I/II) (early-phase heavy).

Top condition: Obesity (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Hanmi Pharmaceutical Company Limited: open-pipeline peers nationwide

Peers matched on 25 registered trials and 28% open enrollment, not the therapeutic-area sidebar.

Hanmi Pharmaceutical Company Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Hanmi Pharmaceutical Company LimitedArcus BiosciencesArcutis BiotherapeuticsArdelyxDrexel University College of MedicineThe University of Texas at DallasUniversity of Arkansas, FayettevilleMerit Medical Systems89bio
Hanmi Pharmaceutical Company Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hanmi Pharmaceutical Company Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 25 trials (± recruiting share)

Sponsors near 28% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hanmi Pharmaceutical Company Limited page

25 registered trials is a research-attention snapshot, not an endorsement of Hanmi Pharmaceutical Company Limited or any single study.

  • 7 of Hanmi Pharmaceutical Company Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Hanmi Pharmaceutical Company Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hanmi Pharmaceutical Company Limited pipeline card: 25 registered trials from official public datasets.Report a data error.